The FDA approved sevabertinib for advanced or metastatic nonsquamous NSCLC harboring HER2 (ERBB2) TKD activating mutations.

The FDA approved camizestrant plus a CDK4/6 inhibitor for hormone receptor–positive, HER2-negative metastatic breast cancer that acquires an ESR1 mutation.

The FDA approved ropeginterferon alfa-2b for the treatment of essential thrombocythemia.

The FDA approved rusfertide for the treatment of patients with polycythemia vera.